Homepage Top Section2

These therapies will be developed using Ryvu’s stimulator of interferon genes (STING) technology. The deal expands Exelixis’ biotherapeutics portfolio by combining its tumour-specific targeting approaches with the Ryvu’s

The collaboration will use ImmunoGen’s linker-payload technology which is directed to new targets that are identified by OBT through its OGAP discovery platform. The two companies will jointly

Zavegepant nasal spray is claimed to be the only small molecule calcitonin gene-related peptide (CGRP) receptor antagonist in an intranasal formulation for the acute treatment of migraine in

The positive opinion for use of Cosentyx either alone or in combination with methotrexate has been given for the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA)

Proceeds from the financing round will be used by the company to advance Inceptor Bio’s CAR-T lead programme to a Phase I clinical trial as well as continue

Grupo Somar is an integrated pharmaceutical company with focus on developing, manufacturing, and marketing branded generic, private label and OTC products aimed at the private market and providing

This multi-year deal builds on the ongoing collaboration with AstraZeneca announced in June last year, to include the development of small molecule inhibitors targeting a second cancer-related epigenetic

Additionally, the FDA’s Division of Neurology I granted its request for a pre-IND meeting for discussing a development path for elamipretide along with products within the approved exon-skipping

The company focuses on transforming the treatment of T Cell-mediated pathologies. New investors, Eli Lilly and Company and Sound Bioventures, took part in the financing round along with